Sight Sciences to Showcase Glaucoma and Dry Eye Data at 2026 ASCRS Meeting
Event summary
- Sight Sciences to present clinical data on OMNI Surgical System and TearCare System at 2026 ASCRS Annual Meeting in Washington, DC.
- OMNI data shows significant reductions in long-term diurnal IOP fluctuations regardless of lens status.
- TearCare results demonstrate early and sustained superiority over Restasis in tear film stability.
- Presentations scheduled for April 11, 2026, including oral and poster sessions.
The big picture
Sight Sciences' ASCRS presentations come as the ophthalmology sector increasingly shifts toward minimally invasive interventions for glaucoma and dry eye disease. The company's focus on clinical validation aligns with broader industry trends favoring data-driven adoption of new technologies. Success in these core markets could position Sight Sciences as a key player in transforming eyecare paradigms.
What we're watching
- Clinical Validation
- How the OMNI and TearCare data will impact physician adoption and market positioning.
- Competitive Dynamics
- Whether Sight Sciences can sustain differentiation against established dry eye treatments like Restasis.
- Regulatory Pathways
- The pace at which positive clinical data translates into expanded regulatory approvals or reimbursement coverage.